SecBot SecBot
8-K ·Filed Jul 14, 2026

XOMA

XOMA Royalty Corp
BULLISH
Impact 8/10
Horizonimmediate Processed4mo ago SEC0001193125-26-302648
Actionable Insight ▲ Bullish

The acquisition has closed; XOMA common and preferred shares are no longer trading. For common holders, the only remaining value is the $39.00 cash per share already received and the CVR tied to litigation outcomes. Monitor the Janssen litigation for potential CVR payouts. No further trading or arbitrage opportunity exists in XOMA securities.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK AT ENTRY AT T+5
Entry
$40.17
T+0 close · Jul 14, 2026 · via day close
Latest settled
0.00%
T+5 · $40.17
Vs SPY
+0.47%
α at T+5
Next horizon
T+20
due 3mo ago
  1. T+0 · Jul 14 $40.17entry
  2. T+1 · 4mo ago 0.00%α −0.40% · $40.17
  3. T+5 · 4mo ago 0.00%α +0.47% · $40.17
  4. T+20 · due 3mo ago Pending
  5. T+60 · due 6w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

XOMA Royalty Corp. completed its acquisition by Ligand Pharmaceuticals on July 14, 2026. Common stockholders received $39.00 per share in cash plus one Contingent Value Right (CVR) per share tied to 75% of net proceeds from pending litigation. The Series A and Series B perpetual preferred stock were redeemed in full, and XOMA's common stock was delisted from Nasdaq. The transaction was approved by over 15.9 million votes in favor at the special meeting.

Key Facts

  • Acquisition by Ligand Pharmaceuticals closed on July 14, 2026
  • Common stockholders received $39.00 per share in cash plus one CVR per share
  • CVR entitles holders to 75% of net proceeds from certain pending litigation
  • Series A (XOMAP) and Series B (XOMAO) perpetual preferred stock were redeemed with all accrued dividends paid
  • XOMA common stock delisted from Nasdaq effective before trading on July 14, 2026
  • Loan agreement with Blue Owl Capital was terminated and fully discharged
  • Shareholder vote: 15,924,106 for, 98,100 against, 11,380 abstentions on merger proposal
  • 17,678,742 shares of common stock outstanding as of record date June 5, 2026
  • Board of directors replaced with Ligand designees: Todd C. Davis, Octavio Espinoza, Andrew Reardon

Financial Impact

Common stockholders received $39.00 per share in cash (approx. $689M based on 17.68M shares) plus CVRs with contingent value from litigation. Preferred stock redeemed at par plus accrued dividends. Loan obligations fully discharged by Ligand.

cash considerationcontingent value rightsredemption of preferred stockdebt termination

Risk Factors

  • CVR value depends entirely on outcome of pending litigation; may be zero
  • Delisting eliminates liquidity for any remaining positions
  • Potential dissenting shareholder appraisal rights (not quantified in filing)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (XOMA), Batch item 10001193125-26-302648
Document: d165297dex991.htm0001193125-26-302648
Document: 0001193125-26-302648-index-headers.html0001193125-26-302648
Document: 0001193125-26-302648-index.html0001193125-26-302648
Document: 0001193125-26-302648.txt0001193125-26-302648
8-K Filing (XOMA), Batch item 60001193125-26-302648
Document: d165297dex991.htm0001193125-26-302648
Document: 0001193125-26-302648-index-headers.html0001193125-26-302648
Document: 0001193125-26-302648-index.html0001193125-26-302648
Document: 0001193125-26-302648.txt0001193125-26-302648

Track record

8 reports on XOMA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jul 27, 202616w ago 15-12G Bearish 7/10 No price data
  2. Jul 14, 202617w ago 8-K Bullish 8/10 Viewing Entry $40.17 to $40.17 · 0.00% +0.47% vs SPY
  3. Jun 12, 202622w ago DEFA14A Bullish 8/10 Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
  4. Jun 12, 202622w ago 8-K Neutral 4/10 Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
  5. Mar 18, 202634w ago Press Release Neutral 3/10 Entry $28.76 to $30.53 ▲ +6.15% +8.37% vs SPY
  6. Mar 18, 202634w ago 8-K Neutral 4/10 Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
  7. Mar 18, 202634w ago Press Release Bullish 8/10 Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
  8. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $26.86 to $28.76 ▲ +7.07% +8.05% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026